These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26843061)

  • 41. Safety data and withdrawal of hepatotoxic drugs.
    Babai S; Auclert L; Le-Louët H
    Therapie; 2021; 76(6):715-723. PubMed ID: 29609830
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France?
    Paludetto MN; Olivier-Abbal P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2012 Dec; 21(12):1289-94. PubMed ID: 22961933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. What Is the Plural of a 'Yellow' Anecdote?
    Evans SJ
    Drug Saf; 2016 Jan; 39(1):1-3. PubMed ID: 26597283
    [No Abstract]   [Full Text] [Related]  

  • 44. [Adverse drug reactions following immunization in Germany pursuant to the German Infection Protection Act and the German Medicinal Products Act from January 1, 2004 to December 31, 2005].
    Weisser K; Meyer C; Petzold D; Mentzer D; Keller-Stanislawski B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2007 Nov; 50(11):1404-17. PubMed ID: 17999134
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Language does not come "in boxes": Assessing discrepancies between adverse drug reactions spontaneous reporting and MedDRA® codes in European Portuguese.
    Inácio P; Airaksinen M; Cavaco A
    Res Social Adm Pharm; 2015; 11(5):664-74. PubMed ID: 25596069
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Vigilance for veterinary medicinal products: Reports of adverse reactions in the year 2016].
    Müntener CR; Müntener C; Kupper J; Naegeli H; Gassner B
    Schweiz Arch Tierheilkd; 2017 Nov; 159(11):581-585. PubMed ID: 29128859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Medicines withdrawn in other countries due to safety concerns: should they continue to be available in the Argentine pharmaceutical market?].
    Buschiazzo H; Dorati C; Iusef Venturini N; Cañas M; Urtasun MA; Marin GH; Prozzi GR; Rivadulla PA; Trionfetti M; Mordujovich Buschiazzo P
    Rev Fac Cien Med Univ Nac Cordoba; 2022 Sep; 79(3):241-247. PubMed ID: 36149072
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reported time to onset of neurological adverse drug reactions among different age and gender groups using metoclopramide: an analysis of the global database Vigibase®.
    Svendsen K; Wood M; Olsson E; Nordeng H
    Eur J Clin Pharmacol; 2018 May; 74(5):627-636. PubMed ID: 29290074
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance.
    Borg JJ; Aislaitner G; Pirozynski M; Mifsud S
    Drug Saf; 2011 Mar; 34(3):187-97. PubMed ID: 21332243
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prescription sequence symmetry analysis: assessing risk, temporality, and consistency for adverse drug reactions across datasets in five countries.
    Pratt N; Chan EW; Choi NK; Kimura M; Kimura T; Kubota K; Lai EC; Man KK; Ooba N; Park BJ; Sato T; Shin JY; Wong IC; Kao Yang YH; Roughead EE
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):858-64. PubMed ID: 25907076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Post-market safety warnings for drugs approved in Canada under the Notice of Compliance with conditions policy.
    Lexchin J
    Br J Clin Pharmacol; 2015 May; 79(5):847-59. PubMed ID: 25393960
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of regulatory guidances and drug regulation on risk minimization interventions in drug safety: a systematic review.
    Nkeng L; Cloutier AM; Craig C; Lelorier J; Moride Y
    Drug Saf; 2012 Jul; 35(7):535-46. PubMed ID: 22702638
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Vigilance for veterinary medicinal products: Reports of adverse reactions in the year 2017].
    Müntener C; Kupper J; Naegeli H; Gassner B
    Schweiz Arch Tierheilkd; 2019 Feb; 161(2):107-112. PubMed ID: 30696613
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
    Aagaard L; Hallgreen CE; Hansen EH
    Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Drug-induced pancreatitis. A review of French spontaneous reports].
    Chebane L; Bagheri H; Hillaire-Buys D; Géniaux H; Yahioui N; Laroche ML; Cottin J; Spreux A; Mosquet B; Pecriaux C; Bellet F; Lambert A; Montastruc JL
    Rev Med Interne; 2015 Sep; 36(9):573-8. PubMed ID: 26045335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database.
    Kumlien E; Lundberg PO
    Seizure; 2010 Mar; 19(2):69-73. PubMed ID: 20036167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detection of adverse drug reactions through the minimum basic data set.
    Salmerón-García A; Cabeza Barrera J; Vergara Pavón MJ; Román Márquez E; Cortés de Miguel S; Vallejo-Rodríguez I; Raya García S; Casado Fernández E
    Pharm World Sci; 2010 Jun; 32(3):322-8. PubMed ID: 20213432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Post-approval safety issues with innovative drugs: a European cohort study.
    Mol PG; Arnardottir AH; Motola D; Vrijlandt PJ; Duijnhoven RG; Haaijer-Ruskamp FM; de Graeff PA; Denig P; Straus SM
    Drug Saf; 2013 Nov; 36(11):1105-15. PubMed ID: 24048690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Spontaneously reported adverse reactions in association with complementary and alternative medicine substances in Sweden.
    Jacobsson I; Jönsson AK; Gerdén B; Hägg S
    Pharmacoepidemiol Drug Saf; 2009 Nov; 18(11):1039-47. PubMed ID: 19650152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Signal Detection of Imipenem Compared to Other Drugs from Korea Adverse Event Reporting System Database.
    Park K; Soukavong M; Kim J; Kwon KE; Jin XM; Lee J; Yang BR; Park BJ
    Yonsei Med J; 2017 May; 58(3):564-569. PubMed ID: 28332362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.